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Abstract
Background: Select patients with peri-ampullary cancers require concomitant colon resection (CR)
during a pancreaticoduodenectomy (PD) for margin-negative resections. This study analysed the
impact of concomitant CR on major morbidity (MM) and mortality.
Methods: National Surgical Quality Improvement Program (NSQIP) patients undergoing PD for peri-
ampullary cancers were identified from 2005 to 2012. A 4 : 1 propensity-score matched analysis iso-
lated the impact of CR upon PD. Risk factors for 30-day MM and mortality were analysed to determine
post-operative sequelae of PD+CR.
Results: From 10 965 PD and 159 PD+CR patients, 624 and 156, respectively, were selected for
4 : 1 matched analysis. PD+CR resulted in a higher MM and mortality (50.0% and 9.0%) versus PD
alone (28.8% and 2.9%, respectively, P < 0.001). Multivariate analysis identified risk factors for MM
after PD: concomitant CR [odds ratio (OR)–3.19, P < 0.001], smoking (OR–1.92, P = 0.005), a lack of
functional independence (OR–3.29, P = 0.018), cardiac disease (OR–2.39, P = 0.011), decreased
albumin (per g/dl, OR–1.38, P = 0.033) and a longer operative time (versus median time, OR–1.56,
P = 0.029). Independent predictors of mortality included concomitant CR (OR–3.16, P = 0.010), ventila-
tor dependence (OR–13.87, P < 0.001) and septic shock (OR–6.02, P < 0.001).
Conclusions: CR was an independent predictor of MM and mortality after a PD. Patients requiring
PD+CR should be identified pre-operatively, maximally optimized and referred to experienced surgeons
at expert centres.
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Introduction
A complete surgical resection with a pancreaticoduodenectomy
(PD) is a required part of a potentially curative multimodality
treatment plan for patients with pancreatic head adenocarci-
noma.1,2 Despite improvements in neoadjuvant and adjuvant
therapies, and surgical techniques, only 15% to 20% of patients
are candidates for a resection owing to the presence of a distant
tumour outside the confines of a resection, or because of locally
advanced disease.2–6 Select patients with peri-ampullary cancers
require a multi-organ resection during a PD to achieve margin-
negative resections.7–12 A margin-negative, or R0, resection is
critical as better oncological outcomes are associated with a
successful R0 resection.4,13–15 However, this aggressive approach
with a multivisceral resection with PD may result in an increase
in major morbidity and/or mortality, leading to delays in adju-
vant therapy and even a decreased survival. Previous studies
have shown that up to one-third of patients undergoing a PD
have significant medical comorbidities and are less likely to be
rescued from major post-operative complications, which sug-
gests that surgeons should identify and optimize these comor-
bidities and utilize pre-habilitation to address functional
deficits before an elective PD.16
This study was presented at the Annual Meeting of the AHPBA, 11-15
March 2015, Miami, Florida.
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Previous single-institution studies have suggested that PD can
be safely combined with concomitant organ and/or vein resec-
tion without a significant difference in outcomes.9–12,17 How-
ever, these studies contained highly selected patients operated
upon at expert centres, which does not necessarily reflect general
outcomes nationally. Within this context, this study sought to
characterize the true major morbidity (MM) and mortality asso-
ciated with PD+CR in a large national dataset. The primary aim
was to compare national rates of post-PD MM and mortality in
patients undergoing PD versus PD+CR. The secondary aims
were to identify risk factors for morbidity and mortality in PD
patients to isolate the independent impact of CR and to deter-
mine strategies surgeons may utilize to optimize correctable
preoperative risk factors and improve patient outcomes.
Patients and methods
Patient and data collection
The American College of Surgeons National Surgical Improve-
ment Program (ACS-NSQIP) is a nationally validated, risk-
adjusted, outcomes-based programme to measure and improve
the quality of surgical care using risk-adjusted clinical data from
public and private hospitals. Analyses of NSQIP have demon-
strated high quality and reproducible data.18 Participating
NSQIP hospitals and their researchers have full access to the
Participant Use Files (PUF) containing de-identified data from
all participating sites. As NSQIP patient information is de-iden-
tified, this study was exempt from University of Kentucky Insti-
tutional Review Board approval. All patients undergoing a PD
for peri-ampullary cancers, with and without CR, from the
2005–2012 NSQIP database, were initially screened using cur-
rent procedural terminology (CPT) codes 48150, 48152, 48153
and 48154. Patients with concurrent CR were identified by CPT
codes 44140, 44141, 44143, 44144, 44145, 44146, 44147, 44150,
44156, 44157, 44158 and 44160 (Table S1). Patients undergoing
a concurrent vein resection were identified by CPT codes
35221, 35251, 35281, 35531 and 35631.
Patients without a post-operative diagnosis of malignancy
were excluded by applying International Classification of Dis-
eases, 9th edition (ICD-9) codes to select only patients with
peri-ampullary cancers as follows: 152, 155.1, 156,156.1, 156.2,
156.9, 157.0, 157.1, 157.2, 157.3, 157.4, 157.8, 157.9, 209.01,
209.3, 235.2, 235.5, 239 and 258.01.
Propensity-score matched analysis
All pre-, intra- and post-operative NSQIP variables were
abstracted for analysis. Propensity score matching was used to
mitigate the inherent selection bias of a retrospective database
analysis. Using all preoperative variables, a propensity score
was generated for each patient. Logistic regression was used to
generate this score as a likelihood of receiving PD versus
PD+CR. A 1:N matching macro assigned matched PD versus
PD+CR cohorts based on the propensity score. Initially, this
was performed as a 1:1 match; however, the size of the PD
cohort was increased in a stepwise manner to maximize the
available patients, while maintaining non-significant differences
between the preoperative variables. This technique converged
at a 4:1 match as optimal for this dataset.
Definitions and variables analysed
Pre-operative risk factors identified were American Society of
Anesthesiology (ASA) class of ≥ 3, diabetes, 10% weight loss in
6 months, current smoker, current alcohol use, a lack of func-
tional dependence, body mass index (BMI) (kg/m2), a history
of chronic obstructive pulmonary disorder (COPD), dyspnea, a
history of cardiac disease, a history of hypertension, albumin
<4 g/dl, haematocrit (Hct) < 39% and pre-operative chemo-
therapy and radiation treatment. Intra-operative risk factors
included a vein resection, total operation time (minutes, med-
ian), operative time > 370 min, peri-operative transfusion and
return to the operating room (OR). Post-operative complica-
tions evaluated were wound infections/complications including
superficial surgical site infection (SSI), deep SSI, organ space
infection (OSI) and wound dehiscence. Other post-operative
complications included pneumonia, failure to wean from the
ventilator, re-intubation, cardiac arrest, a post-operative
myocardial infarction (MI), sepsis, septic shock and the total
length of stay (LOS). MM was defined as any of the following:
pneumonia, re-intubation, ventilator dependence, renal insuffi-
ciency/failure, cardiac events, neurological events, sepsis/septic
shock, return to the OR, dehiscence, organ space infection and
venous thromboembolism. Mortality was defined as death
within 30 days or the index hospitalization.
Statistical analyses
Univariate analyses were performed using non-parametric tests
to compare risk factors for 30-day major morbidity and mortality
in the two cohorts. Categorical variables were reported as num-
ber (n, %) and compared using a chi-squared or Fisher’s Exact
test as appropriate. Non-parametric continuous variables were
reported with medians (range) and compared using the Mann-
Whitney U-test or ANOVA as appropriate. Multivariate analyses
were performed using logistic regression. Candidate models were
chosen using stepwise forward selection and backward elimina-
tion to isolate the impact of CR on PD. The MM model adjusted
for all pre-operative variables, operative time variables and proce-
dure type. The mortality model adjusted for all pre-operative
variables, post-operative variables including morbidity variables
and procedure type. Models were adjusted for multiple compari-
sons and subgroups. Analyses were conducted using SAS©
(version 9.3; SAS Institute Inc., Cary, NC, USA). All tests were
two-sided with significance defined as P < 0.05.
Results
Patients
ACS- NSQIP data extraction identified 10 965 patients under-
going PD and 159 patients undergoing PD+CR in total. Their
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Table 1 Demographic and peri-operative variables in unmatched patients undergoing PD and PD+CR
PD Only PD +CR Total P-value
(N = 10 965) (N = 159) (N = 11 124)
Demographic variables
Race
Caucasian 7061 (64.4%) 96 (60.4%) 7157 (64.3%) 0.294
Non-Caucasian 3904 (35.6%) 63 (39.6) 3967 (35.7%)
Age (years, median) 66.0 64.0 66.0 0.015
18–74 years 58.0–74.0 54.0–73.0 58.0–74.0
75 years and greater 2631 (24.1%) 34 (21.5%) 2665 (24.1%) 0.452
Gender
Male 5767 (52.7%) 95 (59.7%) 5862 (52.8%) 0.075
Female 5198 (47.3%) 64 (40.3%) 5262 (47.2%)
ASA class 3 or higher 7898 (72.0%) 121 (76.1%) 8019 (72.1%) 0.256
Diabetes 2084 (20.2%) 25 (16.9%) 2109 (20.1%) 0.32
10% weight loss in 6 months 2137 (19.5%) 39 (24.5%) 2176 (19.6%) 0.112
Smoker 2145 (19.6%) 38 (23.9%) 2183 (19.6%) 0.172
Alcohol use 245 (3.1%) 3 (2.6%) 248 (3.1%) >0.999
Lack of functional independence 263 (2.4%) 4 (2.5%) 267 (2.4%) 0.794
BMI (kg/m2, median) 26.2 24.5 26.2 0.007
COPD 493 (4.5%) 2 (1.3%) 495 (4.4%) 0.049
Dyspnea 881 (8.0%) 14 (8.8%) 895 (8.0%) 0.723
Cardiac disease 906 (8.3%) 10 (6.3%) 916 (8.2%) 0.369
Hypertension 6071 (55.4%) 75 (47.2%) 6146 (55.2%) 0.039
Albumin <4 g/dl 6901 (69.1%) 113 (76.9%) 7014 (69.2%) 0.043
Hct<39% 6805 (63.3%) 118 (75.2%) 6923 (63.4%) 0.002
Chemotherapy 306 (3.9%) 4 (3.5%) 310 (3.9%) 0.999
Radiation treatment 323 (4.1%) 2 (1.8%) 325 (4.1%) 0.333
Perioperative variables
Intraoperative characteristics
Vein Resection required 276 (2.5%) 8 (5.0%) 284 (2.6%) 0.067
Total operation time (min, median) 359.0 426.0 360.0 <0.001
Operative time > 370 min 6634 (60.5%) 119 (74.8%) 6753 (60.7%) <0.001
Perioperative transfusion 1711 (15.7%) 41 (26.3%) 1752 (15.8%) <0.001
Return to OR 735 (6.7%) 20 (12.6%) 755 (6.8%) 0.003
Wound infection/complication
Superficial SSI 1125 (10.3%) 28 (17.6%) 1153 (10.4%) 0.003
Deep SSI 279 (2.5%) 1 (0.6%) 280 (2.5%) 0.194
Organ space infection 1144 (10.4%) 36 (22.6%) 1180 (10.6%) <0.001
Wound dehiscence 216 (2.0%) 4 (2.5%) 220 (2.0%) 0.559
Postoperative complications
Pneumonia 520 (4.7%) 11 (6.9%) 531 (4.8%) 0.201
Failure to wean from ventilator 580 (5.3%) 20 (12.6%) 600 (5.4%) <0.001
Re-intubation 562 (5.1%) 15 (9.4%) 577 (5.2%) 0.015
Cardiac arrest 139 (1.3%) 6 (3.8%) 145 (1.3%) 0.018
Post-operative MI 90 (0.8%) 3 (1.9%) 93 (0.8%) 0.148
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clinical characteristics are detailed in Table 1. The two popula-
tions are closely, but not completely, similar in their preopera-
tive characteristics. Significant intra-operative differences
between the two groups included all intra-operative variables
except the need for vein resection (P = 0.067).
A total of 780 patients met inclusion criteria for the 4:1 pro-
pensity-score matched analysis (PD=624, PD+CR=156,
Table 2). With the macro-generated propensity score, the
matched cohorts were well matched based on patient demo-
graphics and pre-operative risk factors including administra-
tion of chemotherapy and radiation. The only intra-operative
variable that was statistically different between the groups was
total operative time (P < 0.001).
Univariate analysis of matched cohorts
PD+CR resulted in a significantly higher MM and mortality
(50.0% and 9.0%) versus PD alone (28.8% and 2.9%, respec-
tively, P < 0.001) (Fig. 1). In the matched cohort (n = 156),
80 patients had a MM and 14 patients died (Table 3). Post-
operative complications associated with mortality on univariate
analysis in this group included re-intubation (42.9%, P <
0.001), cardiac arrest (35.7%, P < 0.001), septic shock (50.0%,
P < 0.001) and MM (92.9%, P < 0.001).
Multivariate analyses
Multivariate analysis identified the following independent risk
factors for MM after PD: active smoking (OR–1.92,
P = 0.005), the lack of functional independence (OR–3.29,
P = 0.018), cardiac disease (OR–2.39, P = 0.011), a decreased
albumin (per g/dl, OR–1.38, P = 0.033), a longer operative
time (versus median time 370 min, OR–1.56, P = 0.029) and a
concomitant CR (OR–3.19, P < 0.001, Table 4). Independent
predictors of mortality included ventilator dependence (OR–
13.87, P < 0.001), septic shock (OR–6.02, P < 0.001), and con-
comitant CR (OR-3.16, P = 0.010, Table 5).
Discussion
Contrary to past single-institution reports, this study, using a
4 : 1 propensity-score matched analysis derived from the ACS-
NSQIP database, determined that PD+CR resulted in a signifi-
cantly higher MM and mortality than PD alone. CR was an
independent risk factor for both MM and mortality with
PD+CR patients having three times the likelihood of both MM
and mortality compared with patients undergoing PD alone.
This dramatically increased risk highlights the importance of
identifying patients upfront who may need PD+CR so that
they can be optimized pre-operatively and possibly referred to
surgeons and cancer centres with adequate experience.
Although MM and mortality rates have improved over the
past few decades for patients undergoing PD, this well-matched
analysis of a national dataset determined that the addition of
CR independently increased the risks of both MM and mortal-
ity. To date, there have been few studies that have evaluated
outcomes for patients undergoing PD+CR. Several single-cen-
tre studies have suggested that MM and mortality were compa-
rable between patients undergoing PD+CR versus PD alone,
minimizing the clinical significance of adding CR to PD.9–12,17
However, these studies had an inherent selection bias as they
were single-institution retrospective studies that only reported
patients chosen for surgery, leaving out of the analyses those
who were anatomically unresectable or physiologically inopera-
ble. This study used a large national database to enhance the
statistical power for this rare combination operation, and pro-
pensity score matching to mitigate surgeon-patient selection
bias. In a large observational study, there are often significant
differences between characteristics in the treatment group ver-
sus the control group, and these must be adjusted to determine
the valid treatment effect.19–21 This study used propensity score
matching to reduce this observational bias using a 4 : 1
matched analysis. Comparing Table 1 (unmatched comparison
with differences in preoperative variables) versus Table 2
(matched comparison with balanced preoperative variables)
shows how propensity score matching reduces the inherent
selection bias of a retrospective database.
Similar to the present study, many previous authors showed
the association between morbidity increased with a longer
operative time.8,11 Hartwig et al. also found that an extended
multivisceral resection of 2 or more additional organs as an
independent risk factor for intra-abdominal complications or
need for re-laparotomy, but did not find a significant differ-
ence in mortality after a PD.8 Certainly, none of the indepen-
dent risk factors (besides CR) in the multivariate models for
MM and mortality were surprising. The key finding in the
Table 1 Continued
PD Only PD +CR Total P-value
(N = 10 965) (N = 159) (N = 11 124)
Sepsis 1117 (10.2%) 35 (22.0%) 1152 (10.4%) <0.001
Septic Shock 488 (4.5%) 17 (10.7%) 505 (4.5%) <0.001
Total LOS (days, median) 10.0 13.0 10.0 <0.001
Major morbidity 2949 (26.9%) 80 (50.3%) 3029 (27.2%) <0.001
30-day mortality 304 (2.8%) 14 (8.8%) 318 (2.9%) <0.001
PD, pancreaticoduodenectomy; CR, colon resection; ASA, American Society of Anesthesiology; BMI, body mass index; COPD, chronic obstructive
pulmonary disorder; Hct, hematocrit; OR, operating room; SSI, surgical site infection; MI, myocardial infarction; LOS, length of stay.
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Table 2 Demographic variables of 4 : 1 propensity-score matched population undergoing PD and PD+CR
PD PD+CR Total P-value
(N = 624) (N = 156) (N = 780)
Race
Caucasian 377 (60.4%) 95 (60.9%) 472 (60.5%) 0.913
Non-Caucasian 247 (39.6%) 61 (39.1%) 308 (39.5%)
Age (years, median) 64.0 64.5 64.0 0.699
18–74 years 56.0–73.0 54.0–73.0 55.0–73.0
75 years and greater 129 (20.7%) 34 (21.8%) 163 (20.9%) 0.758
Gender
Male 375 (60.1%) 94 (60.3%) 469 (60.1%) 0.971
Female 249 (39.9%) 62 (39.7%) 311 (39.9%)
ASA class 3 or higher 448 (71.8%) 118 (75.6%) 566 (72.6%) 0.336
Diabetes 116 (19.9%) 24 (16.6%) 140 (19.2%) 0.365
10% weight loss in 6 months 126 (20.2%) 38 (24.4%) 164 (21.0%) 0.253
Smoker 138 (22.1%) 36 (23.1%) 174 (22.3%) 0.796
Alcohol use 14 (3.0%) 3 (2.7%) 17 (3.0%) >0.999
Lack of functional independence 21 (3.4%) 4 (2.6%) 25 (3.2%) 0.609
BMI (kg/m2, median) 25.3 24.7 25.3 0.99
COPD 24 (3.8%) 2 (1.3%) 26 (3.3%) 0.111
Dyspnea 51 (8.2%) 14 (9.0%) 65 (8.3%) 0.746
Cardiac disease 41 (6.6%) 9 (5.8%) 50 (6.4%) 0.715
Hypertension 329 (52.7%) 72 (46.2%) 401 (51.4%) 0.142
Albumin <4 g/dl 420 (74.1%) 113 (77.4%) 533 (74.8%) 0.41
Hct<39% 454 (72.8%) 118 (75.6%) 572 (73.3%) 0.466
Chemotherapy 22 (4.8%) 4 (3.6%) 26 (4.5%) 0.601
Radiation treatment 17 (3.7%) 2 (1.8%) 19 (3.3%) 0.553
Peri-operative variables
Intra-operative characteristics
Vein Resection required 18 (2.9%) 8 (5.1%) 26 (3.3%) 0.163
Total operation time (min, median) 360.5 420.0 370.0 <0.001
Operative time > 370 min 374 (59.9%) 117 (75.0%) 491 (62.9%) <0.001
Perioperative transfusion 117 (18.9%) 39 (25.5%) 156 (20.2%) 0.071
Return to OR 59 (9.5%) 19 (12.2%) 78 (10.0%) 0.31
Wound infection/complication
Superficial SSI 62 (9.9%) 28 (17.9%) 90 (11.5%) 0.005
Deep SSI 22 (3.5%) 1 (0.6%) 23 (2.9%) 0.063
Organ space infection 69 (11.1%) 35 (22.4%) 104 (13.3%) <0.001
Wound dehiscence 15 (2.4%) 4 (2.6%) 19 (2.4%) >0.999
Post-operative complications
Pneumonia 32 (5.1%) 11 (7.1%) 43 (5.5%) 0.347
Failure to wean from ventilator 43 (6.9%) 19 (12.2%) 62 (7.9%) 0.029
Reintubation 43 (6.9%) 15 (9.6%) 58 (7.4%) 0.246
Cardiac arrest 10 (1.6%) 6 (3.8%) 16 (2.1%) 0.107
Post-operative MI 6 (1.0%) 3 (1.9%) 9 (1.2%) 0.394
Sepsis 59 (9.5%) 34 (21.8%) 93 (11.9%) <0.001
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current study was that even adjusting for those independent
risk factors, including neoadjuvant chemotherapy or radiation,
CR significantly increased the risk of MM and mortal-
ity.7,10,16,22,23 One reason CR may increase MM and mortality
is its inherent potential risk for anastomotic leak, infected fluid
collection and/or an abscess. We also determined that even in
the propensity-matched group, OSI is almost two times higher
in the PD+CR group when compared with PD alone (22.4%
versus 11.1%, P < 0.001). SSI were also increased in the
PD+CR group (17.9% versus 9.9%, P = 0.005). OSI was asso-
ciated with MM (P < 0.001). However, septic shock was identi-
fied as an independent risk factor for mortality, which could
be as a result of leak-related OSI after PD+CR. Although some
authors may suggest using OSI as a surrogate for leak, previous
authors demonstrated that OSI are too low in the NSQIP data
file to be used as a surrogate for grade B and C pancreatic fist-
ulae.24 Similarly to our analysis, they suggest that procedure-
specific variables should be used to extrapolate information
regarding outcomes, but this is only applicable with OSI as
these data are not available regarding bile leak and/or delayed
gastric emptying.
Bhayani et al. utilized the ACS-NSQIP database to evaluated
multi-organ resections with PD and determined that CR spe-
cifically was an independent predictor of MM, and also found
that PD+CR had greater rates of wound, pulmonary, cardiac,
thromboembolic, renal and septic complications.25 However,
those authors did not perform statistical measures to correct
for observational and selection bias, and their populations for
PD and PD+CR (n = 9 927 versus 273, respectively) were dif-
ferent from the present study. Furthermore, the present study
determined that current smoking, a lack of functional indepen-
dence, cardiac disease, operative time > 370 min, a decreased
albumin and concomitant CR were independent predictors of
increased MM, highlighting how the surgeon can anticipate
which patients are at a greater risk for complications so that
these patients can be optimized pre-operatively.14,15,26,27
Previous studies suggest that identification of pre-operative
risk factors, especially in patients with multiple co-morbidities
or those in the geriatric population, may help identify and
offer the opportunity for correction of these risk factors prior
to surgery.16,28 The present study also identifies multiple risk
factors for MM and mortality that can potentially be corrected
Table 2 Continued
PD PD+CR Total P-value
(N = 624) (N = 156) (N = 780)
Septic Shock 37 (5.9%) 17 (10.9%) 54 (6.9%) 0.029
Total LOS (days, median) 10.0 13.0 11.0 <0.001
Major morbidity 180 (28.8%) 78 (50.0%) 258 (33.1%) <0.001
30-day mortality 18 (2.9%) 14 (9.0%) 32 (4.1%) <0.001
PD, Pancreaticoduodenectomy; CR, colon resection; ASA, American Society of Anesthesiology; BMI, body mass index; COPD, chronic obstructive
pulmonary disorder; Hct, hematocrit; OR, operating room; SSI, surgical site infection; MI, myocardial infarction; LOS, length of stay.
Figure 1 PD+CR resulted in higher major morbidity and mortality, 50.0% and 9.0%, respectively, versus PD alone 28.8% and 2.9%,
respectively, P < 0.001. Major morbidity and mortality of pancreaticoduodenectomy (PD) with or without colon resection (CR)
HPB 2015, 17, 846–854 ª 2015 International Hepato-Pancreato-Biliary Association
HPB 851
Table 3 Univariate analysis of major morbidity and mortality in patients with PD+CR (N = 156)
Morbidity P-value Mortality P-value
N = 80 N = 14
Demographic variables
Race
Caucasian 43 (53.8%) 0.086 8 (57.1%) 0.796
Non-Caucasian 37 (46.2%) 6 (42.9%)
Age (years, median) 63.0 0.25 72.0 0.097
18–74 years
53.0–73.0 61.0–77.0
75 years and greater 16 (20.3%) 0.699 5 (35.7%) 0.183
Gender
Male 50 (62.5%) 0.476 10 (71.4%) 0.351
Female 30 (37.5%) 4 (28.6%)
ASA class 3 or higher 66 (82.5%) 0.057 12 (85.7%) 0.521
Diabetes 13 (18.1%) 0.713 2 (16.7%) >0.999
10% weight loss in 6 months 17 (21.3%) 0.334 7 (50.0%) 0.044
Smoker 23 (28.8%) 0.149 4 (28.6%) 0.744
Alcohol use 3 (4.8%) 0.249 0 >0.999
Lack of functional independence 77 (96.3%) 0.62 2 (14.3%) 0.039
BMI (kg/m2, median) 25.1 0.611 23.4 0.164
COPD 1 (1.3%) >0.999 0 >0.999
Dyspnea 8 (10.0%) 0.593 3 (21.4%) 0.111
History of cardiac disease 8 (10.0%) 0.098 1 (7.1%) >0.999
History of hypertension 37 (46.3%) 0.815 7 (50.0%) 0.824
Albumin <4 g/dl 53 (70.7%) 0.069 11 (78.6%) >0.999
Hct<39% 57 (72.2%) 0.38 10 (71.4%) 0.749
Chemotherapy 4 (6.5%) 0.124 0 >0.999
Radiation treatment 2 (3.2%) 0.499 0 >0.999
Peri-operative variables
Intra-operative characteristics
Vein Resection required 4 (5.0%) >0.999 2 (14.3%) 0.148
Total operation time (min, median) 432.5 0.521 458.0 0.194
Operative time > 370 min 63 (78.8%) 0.253 10 (71.4%) 0.752
Peri-operative transfusion 24 (31.2%) 0.171 4 (36.4%) 0.481
Return to OR 20 (25.0%) <0.001 7 (50.0%) <0.001
Wound infection/complication
Superficial SSI 17 (21.3%) 0.225 1 (7.1%) 0.467
Deep SSI 1 (1.3%) >0.999 0 >0.999
Organ space infection 36 (45.0%) <0.001 6 (42.9%) 0.088
Wound dehiscence 4 (5.0%) 0.12 1 (7.1%) 0.311
Post-operative complications
Pneumonia 11 (13.8%) <0.001 3 (21.4%) 0.059
Failure to wean from ventilator 20 (25.0%) <0.001 4 (28.6%) 0.08
Re-intubation 15 (18.8%) <0.001 6 (42.9%) <0.001
Cardiac arrest 6 (7.5%) 0.028 5 (35.7%) <0.001
Post-operative MI 3 (3.8%) 0.245 1 (7.1%) 0.243
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pre-operatively to improve patient outcomes. Patients can be
offered tobacco cessation interventions, pre-habilitation and
aggressive immunonutrition, to improve MM rates. Patients
who are anticipated to undergo PD+CR may be offered pre-
operative counselling focused on the calculated increased risk
of MM and mortality. Furthermore, when PD+CR is antici-
pated, this magnitude of surgery could be classified within the
realm of borderline resectable anatomy and could be treated
with neoadjuvant therapy, as opposed to surgery upfront, to
increase the chance of multimodal therapy completion.16 The
time that is bought with this treatment sequencing strategy
offers a window of opportunity to correct further or optimize
risk factors for MM such as nutritional status, performance
status and even cardiopulmonary issues.
Potential limitations of this study include its retrospective
nature and the use of pooled data from a large national
database. This general surgical database cannot account for
outcome variables occurring after 30 days such as 90-day post-
operative complications, which is increasingly reported for
cancer surgery, the impact of complications on adjuvant ther-
apy administration and long-term oncological outcomes. Also,
despite using CPT codes to identify PD and PD+CR, the
specific reason for CR cannot be proven as ACS-NSQIP does
not provide surgical case information regarding colonic mural
involvement versus mesenteric involvement alone as an indica-
tion for colectomy. However, most clinicians would probably
acknowledge that the most common reasons are involvement
of the middle colic artery and/or of the right or transverse
colon mesentery.12,29–31 To that end, we do provide case-
specific information regarding the type of colectomy in
Table S1 which shows that the most common CR performed
with PD is a right colectomy with or without resection of the
terminal ileum (CPT 44140 or 44160, respectively). ACS-
NSQIP does not include final pathologic diagnosis. However,
this study excluded patients without post-operative diagnoses
of malignancy by applying ICD-9 codes to select only patients
with peri-ampullary cancers. Given that the aim of this study
was to analyse short-term outcomes of PD versus PD+CR, the
data obtained from ACS-NSQIP applied to the primary
research question. Despite these limitations, this study contrib-
utes to the current surgical oncology literature as it represents
the largest and most current evaluation of the risk factors for
30-day MM and mortality in patients undergoing PD+CR.
Conclusions
Contrary to previous single-institution studies, this propensity-
score matched analysis using the ACS-NSQIP database showed
that adding CR to PD independently increased the magnitude
of surgery as reflected in the three-fold likelihood of post-PD
MM and mortality. To improve surgical outcomes, patients
who require PD+CR should be identified pre-operatively using
high-resolution imaging, maximally optimized nutritionally
and physiologically, and ideally referred to experienced




Morbidity P-value Mortality P-value
N = 80 N = 14
Sepsis 35 (43.8%) <0.001 1 (7.1%) 0.307
Septic Shock 17 (21.3%) <0.001 7 (50.0%) <0.001
Total LOS (days, median) 17.0 <0.001 13.5 0.4
Major morbidity 80 (100.0%) <0.001 13 (92.9%) <0.001
30-day mortality 13 (16.3%) <0.001 14 (100.0%) <0.001
PD, Pancreaticoduodenectomy; CR, colon resection; ASA, American Society of Anesthesiology; BMI, body mass index; COPD, chronic obstructive
pulmonary disorder; Hct, hematocrit; OR, operating room; SSI, surgical site infection; MI, myocardial infarction; LOS, length of stay.










Cardiac disease 2.39 1.22–4.67 0.011
Operative time >370 min 1.56 1.05–2.34 0.029
Decreased albumin 1.38 1.03–1.85 0.033
Concomitant colon resection 3.19 2.00–5.10 <0.001
PD, Pancreaticoduodenectomy; CR, colon resection.






Ventilator dependence 13.87 5.08–37.87 <0.001




*Based on propensity-score matched analysis with 780 total patients.
PD, Pancreaticoduodenectomy; CR, colon resection. Refer to Table 2.
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